NASDAQ: CRGXCargo Therapeutics Inc Stock
$18.68+0.40 (+2.19%)
Updated Apr 26, 2024
CRGX Price
$18.68
Fair Value Price
N/A
Market Cap
$735.30M
52 Week Low
$13.14
52 Week High
$33.92
P/E
-1.13x
P/B
1.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$98.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$81M
Beta
2.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CRGX Overview
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRGX is good value based on its book value relative to its share price (1.81x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
CRGX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRGX due diligence checks available for Premium users.
Be the first to know about important CRGX news, forecast changes, insider trades & much more!
CRGX News
Valuation
CRGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.13x
Industry
14.88x
Market
41.14x
CRGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.81x
Industry
5.85x
CRGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRGX's financial health
Profit margin
Revenue
$0.0
Net Income
-$32.1M
Profit Margin
0%
CRGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$453.0M
Liabilities
$47.7M
Debt to equity
0.12
CRGX's short-term assets ($409.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRGX's short-term assets ($409.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.0M
Investing
-$3.0M
Financing
$377.9M
CRGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRGX vs Biotech Stocks
Cargo Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.